Patients with ANA & anti-dsDNA | CD4+ TCR Vβ increased usage | CD4 + TCR Vβ decreased usage |
---|---|---|
Patient 1 | None | None |
Patient 2 | Vβ16 (7.4%, Μ + 3SD) | None |
Patient 3 | Vβ4 (2.4%, Μ + 3SD) | Vβ18 (0%, Μ-2SD) |
Patient 4 | Vβ16 (8.2%, Μ + 3SD) | Vβ8 (0.3%, Μ-3SD) |
Vβ13.6 (0%, Μ-3SD) | ||
Patient 5 | Vβ13.2 (7.4%, Μ + 3SD) | |
Vβ4 (2.7%, Μ + 3SD) | ||
Patient 6 | Vβ16 (5.6%, Μ + 3SD) | Vβ5.1 (0.12%, Μ-2SD) Vβ2 (2.83%, Μ-2SD) |
Vβ20 (9.17%, Μ + 3SD) | ||
Vβ12 (9.44%, Μ + 3SD) | ||
Patient 7 | None | None |
Patient 8 | Vβ16 (8%, Μ + 3SD) | Vβ22 (0%, Μ-2SD) |
Vβ20 (7.5%, Μ + 2SD) | ||
Patient 9 | Vβ3 (9%, Μ + 2SD) | Vβ7.1 (0.1%, Μ-2SD) Vβ5.2 (0.2%, Μ-2SD) Vβ2 (0.2%, Μ-2SD) Vβ22 (0.3%, Μ-2SD) |
Vβ16 (7.3%, Μ + 3SD) | ||
Vβ12 (14.2%, Μ + 3SD) |